ALGS Aligos Therapeutics

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024.

Please contact your Piper Sandler representative to schedule a one-on-one meeting.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best-in-class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.

Company

Jordyn Tarazi

Vice President, Investor Relations & Corporate Communications

(650) 910-0427

Media

Michael Fitzhugh

LifeSci Communications

(628) 234-3889



EN
09/04/2024

Underlying

ALGSAligos Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aligos Therapeutics

 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Reports Recent Business Progress and First Quarter...

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the first quarter 2024. “We have executed on a number of key deliverables to position Aligos for success,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President & CEO of Aligo...

May 7, 2024 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on ...

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s first quarter 2024 financial results on Tuesday, May 7, 2024, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that wa...

April 30, 2024 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 fro...

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European...

April 25, 2024 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen...

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col (Ret.), FAASLD, who served as a trusted advisor and the Principal Investigator for the Company’s ongoing Phase 2a HERALD study in metabolic dysfunction-associa...

April 25, 2024 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics to Participate in the Piper Sandler Spring Biophar...

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024. Please contact your Piper Sandler representative to schedul...

April 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch